These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30385283)

  • 1. Impact of Vehicle Physicochemical Properties on Modeling-Based Predictions of Cyclosporine Ophthalmic Emulsion Bioavailability and Tear Film Breakup Time.
    Walenga RL; Babiskin AH; Zhang X; Absar M; Zhao L; Lionberger RA
    J Pharm Sci; 2019 Jan; 108(1):620-629. PubMed ID: 30385283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion.
    Rahman Z; Xu X; Katragadda U; Krishnaiah YS; Yu L; Khan MA
    Mol Pharm; 2014 Mar; 11(3):787-99. PubMed ID: 24423028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric flow field flow fractionation for the characterization of globule size distribution in complex formulations: A cyclosporine ophthalmic emulsion case.
    Qu H; Wang J; Wu Y; Zheng J; Krishnaiah YSR; Absar M; Choi S; Ashraf M; Cruz CN; Xu X
    Int J Pharm; 2018 Mar; 538(1-2):215-222. PubMed ID: 29341918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results.
    Gan L; Gan Y; Zhu C; Zhang X; Zhu J
    Int J Pharm; 2009 Jan; 365(1-2):143-9. PubMed ID: 18773948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.
    Prabhasawat P; Tesavibul N; Mahawong W
    Cornea; 2012 Dec; 31(12):1386-93. PubMed ID: 23135530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea.
    Yenice I; Mocan MC; Palaska E; Bochot A; Bilensoy E; Vural I; Irkeç M; Hincal AA
    Exp Eye Res; 2008 Sep; 87(3):162-7. PubMed ID: 18675411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Product Quality Research for Developing and Assessing Regulatory Submissions for Generic Cyclosporine Ophthalmic Emulsions.
    Belenos A; Wood EL; Hu M; Kozak D; Xu X; Fisher AC
    AAPS J; 2023 Jan; 25(1):20. PubMed ID: 36702976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
    Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
    Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
    Hom MM
    Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits.
    Daull P; Lallemand F; Philips B; Lambert G; Buggage R; Garrigue JS
    Cornea; 2013 Mar; 32(3):345-54. PubMed ID: 23023401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production.
    Liu Y; Wang Y; Yang J; Zhang H; Gan L
    Int J Pharm; 2019 Jun; 565():133-142. PubMed ID: 31075435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tear fluid-eye drops compatibility assessment using surface tension.
    Hotujac Grgurević M; Juretić M; Hafner A; Lovrić J; Pepić I
    Drug Dev Ind Pharm; 2017 Feb; 43(2):275-282. PubMed ID: 27645109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine release and distribution in ophthalmic emulsions determined by pulsatile microdialysis.
    Bellantone RA; Shah KB; Patel PG; Kaplan M; Xu X; Li V; Newman B; Abul Kaisar M
    Int J Pharm; 2022 Mar; 615():121521. PubMed ID: 35093461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid.
    Yamaguchi M; Ueda K; Isowaki A; Ohtori A; Takeuchi H; Ohguro N; Tojo K
    Biol Pharm Bull; 2009 Jul; 32(7):1266-71. PubMed ID: 19571396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.